CPTCF (Cytophage Technologies) Net Income From Continuing Operations: $-2.97 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CPTCF Cytophage Technologies Ltd CPTCF
18 GF Score
Price $0.21
! 1 Warning Sign
View Full Analysis

What is Cytophage Technologies Net Income From Continuing Operations?

Cytophage Technologies CPTCF 18 Net Income From Continuing Operations is $-2.97 Mil as of Dec. 2025. GuruFocus rates CPTCF with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Cytophage Technologies's net income from continuing operations for the six months ended in Dec. 2025 was $-0.58 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.97 Mil.

Cytophage Technologies Net Income From Continuing Operations Historical Data

* Premium members only.

The historical data trend for Cytophage Technologies's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cytophage Technologies Net Income From Continuing Operations Chart

Cytophage Technologies Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Net Income From Continuing Operations
-2.53 -0.52 -3.46 -5.52 -3.00

Cytophage Technologies Semi-Annual Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.87 -0.81 -0.83 -0.75 -0.58
CPTCF
18GF Score
Cytophage Technologies Ltd CPTCF
Net Income From Continuing Operations is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cytophage Technologies Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-2.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income From Continuing Operations of $-2.97 Mil mean?
Cytophage Technologies (CPTCF) has a Net Income From Continuing Operations of $-2.97 Mil as of Dec. 2025. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Cytophage Technologies and its competitors.
Is Cytophage Technologies' Net Income From Continuing Operations too high?
Cytophage Technologies' current Net Income From Continuing Operations is $-2.97 Mil. Overall, Cytophage Technologies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Cytophage Technologies' Net Income From Continuing Operations compare to VRTX and REGN?
Cytophage Technologies' Net Income From Continuing Operations of $-2.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income From Continuing Operations for a Biotechnology company?
A good Net Income From Continuing Operations depends on the Biotechnology industry context. However, Net Income From Continuing Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income From Continuing Operations mean?
A high Net Income From Continuing Operations can signal that a stock is expensive relative to its fundamentals. The total net income from continuing operations as record on a company's cash-flow statement. View historical data for Cytophage Technologies and its competitors. Cytophage Technologies's current Net Income From Continuing Operations is $-2.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cytophage Technologies stock overvalued right now?
Cytophage Technologies (CPTCF) has a current Net Income From Continuing Operations of $-2.97 Mil. The current Net Income From Continuing Operations is $-2.97 Mil. Cytophage Technologies' overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income From Continuing Operations calculated?
Net Income From Continuing Operations is calculated from a company's financial statements. For Cytophage Technologies (CPTCF), the current Net Income From Continuing Operations is $-2.97 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cytophage Technologies Business Description

Other Exchanges CYTO.H:Canada
Address 400 Fort Whyte Way, Suite 200A, Oak Bluff, MB, CAN, R4G 0B1
Cytophage Technologies Ltd is a Canadian biotechnology company engaged in the development of bacteriophages using molecular genetics and synthetic biology techniques. The company focuses on developing bacteriophage-based solutions to address bacterial challenges affecting animal health, human health, and food security, including antibiotic-resistant bacterial strains.
18GF Score

Get the complete analysis for CPTCF

Net Income From Continuing Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.21
Price